Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy
Status:
Not yet recruiting
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
Patients with HER-2 positive breast cancer who have poor outcomes after endocrinotherapy and
standard chemotherapy can be significantly improved by the use of anti-HER-2 monoclonal
antibody trastuzumab. In the current clinical practice of neoadjuvant therapy, trastuzumab
combined with chemotherapy can significantly increase the pCR and improve the outcomes in
patients. However, there seems to be no available treatment for patients who have no pCR and
still have residual tumors except for sequential trastuzumab treatment for 1 year. Compared
with trastuzumab, a HER-2 macromolecule inhibitor, pyrotinib has a different site of action
and an increased EGFR target. Compared with lapatinib, a small molecule inhibitor of EGFR and
HER-2, pyrotinib is an irreversible inhibitor, with the ability to achieve a better curative
effect at a lower human plasma exposure level. This trial is designed to evaluate the
effectiveness and safety of trastuzumab combined with pertuzumab followed by sequential
pyrotinib treatment in non-pCR patients after neoadjuvant therapy.